share_log

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

HC Wainwright & Co.對協同診斷保持中立,將目標股價下調至2美元
Benzinga ·  2023/08/14 06:46

HC Wainwright & Co. analyst Yi Chen maintains Co-Diagnostics (NASDAQ:CODX) with a Neutral and lowers the price target from $3 to $2.

HC Wainwright&Co.分析師陳毅維持共同診斷公司(納斯達克代碼:CODX)的中性,並將目標價從3美元下調至2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論